Scopus
YÖKSİS Eşleşti
Pharmacokinetics and pharmacokinetic interactions of orally administered oxfendazole and oxyclozanide tablet formulation to sheep
Journal of Veterinary Pharmacology and Therapeutics · Ocak 2023
YÖKSİS Kayıtları
Pharmacokinetics and pharmacokinetic interactions of orally administered oxfendazole and oxyclozanide tablet formulation to sheep
Journal of veterinary pharmacology and therapeutics · 2023 SCI-Expanded
PROFESÖR KAMİL ÜNEY →
Pharmacokinetics and pharmacokinetic interactions of orally administered oxfendazole and oxyclozanide tablet formulation to sheep
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS · 2022 SCI
PROFESÖR BÜNYAMİN TRAŞ →
Pharmacokinetics and pharmacokinetic interactions of orally administered oxfendazole and oxyclozanide tablet formulation to sheep
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS · 2023 SCI-Expanded
PROFESÖR BÜNYAMİN TRAŞ →
Makale Bilgileri
DergiJournal of Veterinary Pharmacology and Therapeutics
Yayın TarihiOcak 2023
Cilt / Sayfa46 · 34-41
Scopus ID2-s2.0-85139165613
Özet
The combination of oxfendazole and oxyclozanide is used to provide activity against fluke and gastrointestinal nematodes. This study aimed to determine both the pharmacokinetics of oxfendazole (7.5 mg/kg) and oxyclozanide (15 mg/kg) tablet formulation administered orally to sheep and whether there is a pharmacokinetic interaction between these two drugs. The study was conducted in a three-period, crossover pharmacokinetic design and on six healthy Awassi sheep 1–3 years of age. The plasma concentrations of oxfendazole and its metabolites (fenbendazole and fenbendazole sulphone) and oxyclozanide were determined by high-performance liquid chromatography using an ultraviolet detector. Compounds recovered in plasma when oxfendazole was administered alone or combined with oxyclozanide were oxfendazole, fenbendazole sulphone, and fenbendazole, respectively. When oxfendazole was administered alone and co-administered with oxyclozanide, the AUCFBZ/AUCOFZ was 0.26 and 0.23, respectively, and the AUCFBZSO2/AUCOFZ was 0.35 and 0.32, respectively. The volume of distribution (Vz/F) of oxfendazole was large in both groups. Oxyclozanide did not change the plasma disposition of oxfendazole. When the oxyclozanide tablet formulation was administered alone, the elimination half-life (21.35 h) and the Vz/F (940.17 ml/kg) were long and large, respectively. The area under the curve (AUC) and the maximum plasma concentration of oxyclozanide were significantly larger and higher, respectively, in the oxyclozanide plus oxfendazole group (1146.61 h × μg/ml and 29.80 μg/ml) compared with the oxyclozanide group (491.44 h × μg/ml and 14.24 μg/ml) while a significant decrease in apparent Vz/F (940.17 vs 379.14 ml/kg) and total clearance (30.52 vs 13.08 ml/h/kg) was detected. In conclusion, co-administration with oxfendazole causing an increase in the plasma profile of oxyclozanide may increase the antiparasitic activity of oxyclozanide.
Yazarlar (7)
1
Zeynep Ozdemir Kutahya
2
Sinan Kandir
3
H. Eser Faki
4
Kamil Üney
ORCID: 0000-0002-8674-4873
5
B. Traş
6
Mehmet Celik
7
Osman Torun
Anahtar Kelimeler
interaction
oral
oxfendazole
oxyclozanide
pharmacokinetics
sheep
Kurumlar
Çukurova Üniversitesi
Adana Turkey
Selçuk Üniversitesi
Selçuklu Turkey
Metrikler
2
Atıf
7
Yazar
6
Anahtar Kelime